@article{fd94b2bbb5964aee92cbca687da4eb56,
title = "Utilization of Heart Failure Medications in Duchenne Muscular Dystrophy Patients with Left Ventricular Systolic Dysfunction",
author = "A.K. Lal and C.A. Wittlieb-Weber and C.R. Villa and C. Cunningham and M.J. Bock and K.E. Gambetta and J.N. Johnson and K.R. Schumacher and S.P. Law and S.R. Deshpande and S.C. West and J.M. Friedland-Little and I.D. Lytrivi and M.A. McCulloch and Z. Ou and A.P. Presson and R.J. Butts and Bock, \{Matthew J.\}",
note = "Current guidelines for the management of left ventricular systolic dysfunction (LVSD) in Duchenne Muscular Dystrophy (DMD) recommend angiotensin converting enzyme (ACE) inhibitors (class IIa). Little is known about the historic use of HF medications in Duchenne Muscular Dystrophy (DMD) and LVSD.",
year = "2019",
month = apr,
day = "1",
doi = "10.1016/J.HEALUN.2019.01.1186",
language = "American English",
volume = "38",
journal = "Journal of Heart and Lung Transplantation",
}